Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Watson

- PMLiVE

Scotland first in UK to back Pfizer’s Inlyta

SMC also recommends Astellas' Xtandi but not Pfizer's Bosulif

- PMLiVE

Pfizer slams UK drug pricing plan

BioIndustry Association 
also challenges revision to PPRS

- PMLiVE

Pfizer sales down but oncology shows promise

Toll of patent expiries continues

- PMLiVE

Pfizer calls for mHealth to be prioritised

Wants more action to support mobile health in developing countries' ageing populations

- PMLiVE

Xeljanz effective in psoriasis says Pfizer

Data backs extension of drug’s indications

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

Adobe CEO joins Pfizer board

Shantanu Narayen joins corporate governance and science and technology committees

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

- PMLiVE

ViiV gets US nod for HIV drug dolutegravir

GSK and Pfizer joint venture on course for first drug launch

- PMLiVE

Pfizer sales dip as net income surges in Q2

Lipitor performance weighs heavy on the figures

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links